In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Malignant fibrous histiocytoma (MFH) is a type of cancer that typically occurs in soft tissues, such as the muscles and tendons. When it starts in the bones, doctors call it MFH of the bone. The up-to ...

Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial. According to interim results from the phase 2 SARC-028 trial, Keytruda (pembrolizumab) ...

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with ...

According to cytogenetic aberrations, sarcomas can be categorized as complex or simple karyotype tumors. Alternative lengthening of telomeres is a telomere-maintenance mechanism common in sarcomas.

Sarcomas - cancers of the connective tissues like muscles, joints, fat and bone - come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...

Some types of sarcomas elicit a greater immune response than others, which sheds light on how immunotherapy could be used for this connective-tissue cancer, according to a new study. Sarcomas -- ...

Immune checkpoint blockade therapy works by preventing the binding of checkpoint and partner proteins, thereby allowing T cells to continue their work of attacking and killing cancer cells. A team ...